Comparative clinical profile of patients of Benign Prostatic Hyperplasia (BPH) with and without Metabolic Syndrome: a prospective observational study
Keywords:Benign prostatic hyperplasia, Metabolic Syndrome, Prostatic profile
Background: Benign Prostatic Hyperplasia (BPH) is one of common disorder in men of old age group. The pathogenesis of BPH is multi-factorial and still not been fully elucidated. There are numerous reports which suggest possible link between several metabolic alterations known as Metabolic Syndrome. In the present study, the aim was to establish relation between Benign Prostatic Hyperplasia and Metabolic Syndrome and to find out effects of therapeutic intervention of Metabolic Syndrome on prostatic parameters.
Methods: 93 patients of Benign Prostatic Hyperplasia enrolled who met qualifying criteria for inclusion in study and divided into three groups on the basis of Metabolic Syndrome and its treatment administered. Administration of alpha adrenergic blocker was common to all patients of all groups. Metabolic parameters including Fasting blood glucose, High-density lipoprotein (HDL), Triglycerides (TGs), waist circumference and prostatic parameters that is prostate volume, prostate specific antigen (PSA), uroflometry, International prostate symptom score (IPSS) were assessed at baseline, after 3 and 6 months follow-up. Further appropriate statistical tests were applied for comparison of parameters among groups.
Results: Patients receiving no treatment for Metabolic Syndrome were having most deranged prostatic parameters as compared to patients without Metabolic Syndrome or patients with Metabolic Syndrome receiving treatment for same. Further patients receiving treatment for Metabolic Syndrome and alpha adrenergic blocker were having better clinical profile than patients of alpha adrenergic blocker alone.
Conclusions: These findings show probable link between Metabolic Syndrome and worse prostatic profile. Metabolic Syndrome must be looked for and treated in patients of Benign Prostatic Hyperplasia. Metabolic derangements must not be overlooked and must be treated accordingly.
Strandberg JD. Comparative pathology of benign prostatic hyperplasia. In: Lepor H, ed. Prostatic Diseases. Philadelphia: WB Saunders; 2000:329-343.
Shapiro E, Lepor H. Pathophysiology of clinical benign prostatic hyperplasia.Urol Clin North Am. 1995;22:285-90.
Nitti VW. Diagnosis of obstructive uropathy. In: Lepor H, ed. Prostatic Diseases. Philadelphia: WB Saunders; 2000:197-209.
Roehrborn CG, Pickens GJ, Carmody T. 3rd. Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology. 1996;47:59-66.
Jepsen JV, Bruskewitz RC. Clinical manifestations and indications for treatment. In: Lepor H, ed. Prostatic Diseases. Philadelphia: WB Saunders; 2000:127-142.
Lepor H, Shapiro E. Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. J. Urol. 1984;132:1226-9.
Shaw JE, Chisholm DJ. Epidemiology and prevention of type 2 diabetes and the metabolic syndrome, Medical Journal of Australia. 2003;7(179):379-83.
Grundy SM, Cleeman JI, Daniels SR. Diagnosis and management of the metabolic syndrome: an American Heart Association/NationalHeart, Lung, and Blood Institute scientific statement, Circulation. 2005;17(112):2735-52.
Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), Journal of the American Medical Association, 2001;285(19):2486-97.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabetic Medicine, 1998;7(15):539-53.
Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR), Diabetic Medicine. 1999;5(16):442-3.
Einhorn. Endocr Pract. American College of Endocrinology Position Statement on the Insulin Resistance Syndrome. 2003;9(No. 3):236-52.
Desroches S, Lamarche B. The evolving definitions and increasing prevalence of the metabolic syndrome, Applied Physiology, Nutrition and Metabolism. 2007;1(32):23-32.
Kolovou GD, Anagnostopoulou KK, Salpea KD, Mikhailidis DP. The prevalence of metabolic syndrome in various populations. The American Journal of the Medical Sciences. 2007;6(333):362-71.
Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol. 1994;140:989-1002.
Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia.J Urol. 2002;168:599-604.
Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int. 2005;96:88-92.
Hammarsten J, Högstedt B. Hyperinsulinemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39:151-8.
Joseph MA, Harlow SD, Wei JT. Risk factors for lower urinary tract symptoms in a population-based sample of African American men. Am J Epidemiol. 2003;157:906-14.
Sawant A, Mankeshwar R, Shah S, Raghavan R, Dhongde G, Raje H, et al. Prevalence of Metabolic Syndrome in Urban India. Cholesterol. 2011.
Chang SL, Harshman LC, Presti JC. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol. 2010;28(25):3951-7.
Cyrus-David MS, Weinberg A, Thompson T, Kadmon D. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol. 2005;173(6):1923-5.
Jayalath V, Ireland C, Augustin L, Stephanie N, Mirrahimi A, De Souza R, et al. The Association Between Serum Prostate-Specific Antigen and Glycemic Index, Glycemic Load, and Metformin in Individuals with Diabetes: a Cross-sectional Analysis. The FASEB Journal. 2015;1(29):406.8.
Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 2009;69:1774-80.
Park YW, Kim SB, Kwon H, Kang HC, Cho K, Lee KI, et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology. 2013;82(3):674-9.